This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GE HealthCare (GEHC) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in GE HealthCare (GEHC). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
GE HealthCare Technologies (GEHC) Laps the Stock Market: Here's Why
by Zacks Equity Research
GE HealthCare Technologies (GEHC) concluded the recent trading session at $86.21, signifying a +1.96% move from its prior day's close.
GE HealthCare's (GEHC) New Tie-Up to Boost Patient Outcomes
by Zacks Equity Research
GE HealthCare's (GEHC) latest partnership is likely to benefit global healthcare systems by enhancing Elekta's RT offerings with its MIM Software medical imaging management solutions.
Here's Why GE HealthCare Technologies (GEHC) Gained But Lagged the Market Today
by Zacks Equity Research
GE HealthCare Technologies (GEHC) reachead $84.55 at the closing of the latest trading day, reflecting a +0.07% change compared to its last close.
GE HealthCare's (GEHC) Voluson to Aid Women's Health Imaging
by Zacks Equity Research
GE HealthCare (GEHC) announces its latest AI-powered Voluson Signature 20 and 18 ultrasound systems, which are likely to provide effective and efficient care for conditions impacting women's health.
Investors Heavily Search GE HealthCare Technologies Inc. (GEHC): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching GE HealthCare (GEHC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
GE HealthCare (GEHC), RSNA Unite to Aid Breast Cancer Imaging
by Zacks Equity Research
GE HealthCare (GEHC) and RSNA collaborate to provide radiologists at Muhimbili National Hospital a test mammography technology and advanced imaging training to aid in the treatment of breast cancer.
GE HealthCare Technologies (GEHC) Stock Moves -0.17%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, GE HealthCare Technologies (GEHC) stood at $86.13, denoting a -0.17% change from the preceding trading day.
GE HealthCare (GEHC) to Showcase Enhanced Breast Cancer Imaging
by Zacks Equity Research
GE HealthCare's (GEHC) latest breast cancer detection technology is likely to enhance the detection and diagnosis of breast cancer and improve patient outcomes.
Medtronic's (MDT) Sphere-360 PFA Study Outcome Favorable
by Zacks Equity Research
Medtronic's (MDT) Sphere-360 catheter is designed to simplify the atrial fibrillation process while increasing efficiency and giving long-lasting lesions.
Here's Why GE HealthCare Technologies (GEHC) Fell More Than Broader Market
by Zacks Equity Research
In the most recent trading session, GE HealthCare Technologies (GEHC) closed at $87.71, indicating a -0.86% shift from the previous trading day.
iRhythm Technologies (IRTC) Surges 4.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
GE HealthCare's (GEHC) New Launch to Enhance Cardiac Care
by Zacks Equity Research
GE HealthCare's (GEHC) latest offering is likely to expand access to cardiac care by enabling more medical professionals to be able to capture cardiac images.
Wall Street Analysts See GE HealthCare (GEHC) as a Buy: Should You Invest?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), GE HealthCare (GEHC) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GE HealthCare's (GEHC) PVA to Aid in Capturing Prostate Volume
by Zacks Equity Research
GE HealthCare (GEHC) announces the launch of Prostate Volume Assist AI-enabled urology software feature, which is likely to boost prostate imaging, capture prostate volume and increase workflow.
GE HealthCare (GEHC) to Sell IONIC's FDA-Cleared nCommand Lite
by Zacks Equity Research
GE HealthCare (GEHC) announces the FDA approval of IONIC Health's nCommand Lite technology, which it will distribute for multi-vendor, multi-modality remote operations purposes exclusively.
Fresenius Medical (FMS) to Unveil Training on Augmented Reality
by Zacks Equity Research
Fresenius Medical (FMS) is launching digital learning elements with hands-on training for Kidney Replacement Therapy leveraging Augmented Reality.
GE HealthCare (GEHC) Uses AI Solution to Boost Medical Imaging
by Zacks Equity Research
GE HealthCare's (GEHC) SonoSAMTrack demonstrates its pliability and applicability in ultrasound image segmentation by using NVIDIA's technology.
GE HealthCare (GEHC) Renews HealthCare Alliance With Hartford
by Zacks Equity Research
GE HealthCare (GEHC) and Hartford Healthcare announce the renewal of The Care Alliance. The renewal will extend the collaboration through 2030, which started back in 2016.
Earnings Growth & Price Strength Make GE HealthCare Technologies (GEHC) a Stock to Watch
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GE HealthCare (GEHC) Advances AI Alliance to Improve Workflow
by Zacks Equity Research
GE HealthCare's (GEHC) evolution of its AI collaboration is likely to lead to digital and AI transformation and provide better patient care and outcomes.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GE HealthCare (GEHC) AI Model to Predict Immunotherapy Response
by Zacks Equity Research
GE HealthCare (GEHC) announces statistics on AI models that collect clinical data to accurately predict the effectiveness and toxicity of cancer immunotherapy.